Literature DB >> 21277919

Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions.

Natalya Rapoport1, Kweon-Ho Nam, Roohi Gupta, Zhongao Gao, Praveena Mohan, Allison Payne, Nick Todd, Xin Liu, Taeho Kim, Jill Shea, Courtney Scaife, Dennis L Parker, Eun-Kee Jeong, Anne M Kennedy.   

Abstract

Perfluorocarbon nanoemulsions can deliver lipophilic therapeutic agents to solid tumors and simultaneously provide for monitoring nanocarrier biodistribution via ultrasonography and/or (19)F MRI. In the first generation of block copolymer stabilized perfluorocarbon nanoemulsions, perfluoropentane (PFP) was used as the droplet forming compound. Although manifesting excellent therapeutic and ultrasound imaging properties, PFP nanoemulsions were unstable at storage, difficult to handle, and underwent hard to control phenomenon of irreversible droplet-to-bubble transition upon injection. To solve the above problems, perfluoro-15-crown-5-ether (PFCE) was used as a core forming compound in the second generation of block copolymer stabilized perfluorocarbon nanoemulsions. PFCE nanodroplets manifest both ultrasound and fluorine ((19)F) MR contrast properties, which allows using multimodal imaging and (19)F MR spectroscopy for monitoring nanodroplet pharmacokinetics and biodistribution. In the present paper, acoustic, imaging, and therapeutic properties of unloaded and paclitaxel (PTX) loaded PFCE nanoemulsions are reported. As manifested by the (19)F MR spectroscopy, PFCE nanodroplets are long circulating, with about 50% of the injected dose remaining in circulation 2h after the systemic injection. Sonication with 1-MHz therapeutic ultrasound triggered reversible droplet-to-bubble transition in PFCE nanoemulsions. Microbubbles formed by acoustic vaporization of nanodroplets underwent stable cavitation. The nanodroplet size (200nm to 350nm depending on a type of the shell and conditions of emulsification) as well as long residence in circulation favored their passive accumulation in tumor tissue that was confirmed by ultrasonography. In the breast and pancreatic cancer animal models, ultrasound-mediated therapy with paclitaxel-loaded PFCE nanoemulsions showed excellent therapeutic properties characterized by tumor regression and suppression of metastasis. Anticipated mechanisms of the observed effects are discussed.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277919      PMCID: PMC3133819          DOI: 10.1016/j.jconrel.2011.01.022

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  102 in total

Review 1.  19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance.

Authors:  Jian-xin Yu; Vikram D Kodibagkar; Weina Cui; Ralph P Mason
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

2.  Acoustic droplet vaporization threshold: effects of pulse duration and contrast agent.

Authors:  Andrea H Lo; Oliver D Kripfgans; Paul L Carson; Edward D Rothman; J Brian Fowlkes
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2007-05       Impact factor: 2.725

Review 3.  Molecular imaging and therapy of atherosclerosis with targeted nanoparticles.

Authors:  Samuel A Wickline; Anne M Neubauer; Patrick M Winter; Shelton D Caruthers; Gregory M Lanza
Journal:  J Magn Reson Imaging       Date:  2007-04       Impact factor: 4.813

Review 4.  Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis.

Authors:  Shelton D Caruthers; Tillmann Cyrus; Patrick M Winter; Samuel A Wickline; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2009 May-Jun

5.  Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures.

Authors:  Rajiv Chopra; Natalia Vykhodtseva; Kullervo Hynynen
Journal:  ACS Chem Neurosci       Date:  2010-05-19       Impact factor: 4.418

Review 6.  Therapeutic applications of lipid-coated microbubbles.

Authors:  Evan C Unger; Thomas Porter; William Culp; Rachel Labell; Terry Matsunaga; Reena Zutshi
Journal:  Adv Drug Deliv Rev       Date:  2004-05-07       Impact factor: 15.470

7.  Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy.

Authors:  Zhonggao Gao; Anne M Kennedy; Douglas A Christensen; Natalya Y Rapoport
Journal:  Ultrasonics       Date:  2007-11-19       Impact factor: 2.890

8.  Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results.

Authors:  M Behan; D O'Connell; R F Mattrey; D N Carney
Journal:  AJR Am J Roentgenol       Date:  1993-02       Impact factor: 3.959

9.  Fibrinogen adsorption by PS latex particles coated with various amounts of a PEO/PPO/PEO triblock copolymer.

Authors:  M Bohner; T A Ring; Natalya Rapoport; K D Caldwell
Journal:  J Biomater Sci Polym Ed       Date:  2002       Impact factor: 3.517

10.  Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons.

Authors:  Richard Southworth; Megan Kaneda; Junjie Chen; Lei Zhang; Huiying Zhang; Xiaoxia Yang; Reza Razavi; Gregory Lanza; Samuel A Wickline
Journal:  Nanomedicine       Date:  2009-01-19       Impact factor: 5.307

View more
  128 in total

Review 1.  Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Anthony J McGoron
Journal:  Appl Biochem Biotechnol       Date:  2011-09-27       Impact factor: 2.926

Review 2.  Therapeutic potential of ultrasound microbubbles in gastrointestinal oncology: recent advances and future prospects.

Authors:  Tatiana D Khokhlova; Yasser Haider; Joo Ha Hwang
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 3.  Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.

Authors:  Nazila Kamaly; Basit Yameen; Jun Wu; Omid C Farokhzad
Journal:  Chem Rev       Date:  2016-02-08       Impact factor: 60.622

4.  Design of ultrasonically-activatable nanoparticles using low boiling point perfluorocarbons.

Authors:  Paul S Sheeran; Samantha H Luois; Lee B Mullin; Terry O Matsunaga; Paul A Dayton
Journal:  Biomaterials       Date:  2012-01-29       Impact factor: 12.479

Review 5.  Ultrasound-responsive droplets for therapy: A review.

Authors:  H Lea-Banks; M A O'Reilly; K Hynynen
Journal:  J Control Release       Date:  2018-11-29       Impact factor: 9.776

Review 6.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

Review 7.  Nanotechnologies for noninvasive measurement of drug release.

Authors:  Thomas Moore; Hongyu Chen; Rachel Morrison; Fenglin Wang; Jeffrey N Anker; Frank Alexis
Journal:  Mol Pharm       Date:  2013-11-26       Impact factor: 4.939

8.  Targeted drug delivery with focused ultrasound-induced blood-brain barrier opening using acoustically-activated nanodroplets.

Authors:  Cherry C Chen; Paul S Sheeran; Shih-Ying Wu; Oluyemi O Olumolade; Paul A Dayton; Elisa E Konofagou
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

9.  Multiple-Exposure Drug Release from Stable Nanodroplets by High-Intensity Focused Ultrasound for a Potential Degenerative Disc Disease Treatment.

Authors:  Khoi Nguyen; Hsuan-Yeh Pan; Kevin Haworth; Eric Mahoney; Karla P Mercado-Shekhar; Chia-Ying Lin; Zhe Zhang; Yoonjee C Park
Journal:  Ultrasound Med Biol       Date:  2018-10-26       Impact factor: 2.998

10.  Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes.

Authors:  Feng-Ying Huang; Jing Lei; Yan Sun; Fei Yan; Bin Chen; Liming Zhang; Zhuoxuan Lu; Rong Cao; Ying-Ying Lin; Cai-Chun Wang; Guang-Hong Tan
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.